Please identify the type of investor you are

By choosing an option you are acknowledging that this information is accurate and correctly identifies you.

SGH Medical Technology Fund

To provide long-term capital growth by investing in a portfolio of medical technology companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices & equipment, medical data, information technology (e-health) and robotics.

Before making a decision about whether to make an investment in the Fund, please read the Fund’s Target Market Determination (TMD) and Product Disclosure Statement (PDS) (including all incorporated information) to ensure the features of the Fund as described in the TMD and PDS aligns with your objectives, financial situation and needs.

Monthly Fact Sheet
How to invest

At a Glance

APIR code ETL2825AU mFund code - Minimum investment $20,000 Management cost 1.33% Distributions per annum 1 Commencement date 24/06/2021 Asset class Equity Benchmark S&P/ASX 200 Health Care Accumulation Index
Investment objective To provide long-term capital growth by investing in a portfolio of medical technology companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices & equipment, medical data, information technology (e-health), and robotics. Annual report Download
Please refer to the current PDS, reference guide and TMD for further details including any additional fees that may be applicable.

Investment strategy

The Investment Manager seeks to achieve long-term capital growth by focusing stock selection on:

  1. Share valuation
  2. Company management and industry structure
  3. Behavioural factors to determine investment-timing

It is intended that the investment portfolio will consist of 40 to 60 companies split between:
Mature Growth – companies that have established medical products, generate revenue and are profitable. Typically, the medical technology is hard to disrupt or replicate and has a leading market position, e.g. CSL Limited.

Developing Growth – companies that have disruptive intellectual property in the medical technology space. Typically, these companies are in late-stage clinical trials or have registered or approved medical products, growing market access, and early-stage revenue.

Seed – companies that are involved in drug discovery, clinical trials or disruptive medical technology, e.g., start-ups. Typically, these are fast-growing and highly innovative companies with exponential growth potential from successful medical product commercialisation.

Unlisted and pre-Initial Public Offering (IPO) companies – these companies will typically reside in the “Seed” and “Developing Growth” stage of their life-cycle as defined above.

Investment parameters

  • The Fund will invest predominantly in medical technology companies and securities listed on the Australian Securities Exchange (ASX).
  • No more than 30% of the portfolio to be invested in international companies
  • Unlisted companies & pre-IPO companies with maximum portfolio exposure of 20%
  • Minimum number of stocks 40 (no maximum limit)
  • Maximum cash holding of 20%
  • No more than 10% of the market value of the portfolio to be held in any company
  • No more than 10% of a company’s issued capital
  • The Fund is not permitted to be geared or deal in derivatives
  • The Fund can borrow up to 5% of NAV to meet redemption requests

Performance as at 31 July 2026. Powered by data from Financial Express. For funds with less than 5 yrs performance history, refer to fact sheet for since inception returns.

 
Performance
Performance 1M 3M 6M 1Y 3Y 5Y 7Y 10Y Entry Nav Exit Date History
MOREBACK
Fund Name -4.53% -5.28% -21.92% -26.37% -8.52% -9.12% - - $0.6582 $0.6559 $0.6536 13/08/2026

HOW TO INVEST

Existing SGH investor with Apex investor number:

  1. Download and read PDS, reference guide and Target Market Determination (TMD).
  2. Complete additional investment form and send to Apex Fund Services Unit Registry.

Please contact Apex Fund Services at 1300 133 451 if you require assistance.

Not an existing SGH investor:

  1. Download and read PDS, reference guide and Target Market Determination (TMD).
  2. Submit application form online.

OR

  1. Download and read PDS, reference guide and Target Market Determination (TMD).
  2. Complete an application form and send to Apex Fund Services Unit Registry.

Product Disclosure Statement (PDS)

Reference Guide

Target Market Determination (TMD)

Online application portal

Application form

Additional investment form for existing investor

RESEARCH RATINGS

INVESTMENT TEAM

Rory Hunter Portfolio Manager Rory joined SGH in 2019 as part of the merger with DMP Asset Management. Prior to joining DMP in October… Adrian Di Mattina Portfolio Manager Adrian joined SGH in 2001 as one of the founding principals. He is the Portfolio Manager of the SGH Emerging… Sophie Smith Portfolio Manager Sophie joined SGH in June 2021 as an Investment Analyst in the Emerging Companies team, focussing specifically on the SGH…

FUNDS DISTRIBUTION TEAM

Anthony Cochran Head of Distribution Anthony joined SGH in April 2019. He has over 25 years of financial services experience and at SGH is responsible… Alastair McKibbin Head of Research and Consultants Alastair joined SGH in January 2025. Prior to this, he worked at American Century Investments for over five years, most… Matthew Potter Senior Investment Specialist Matthew joined SGH in July 2019. He has over 30 years of investment market experience and is responsible for the…